Aerie Pharmaceuticals PT Raised to $37.00 (AERI)
Equities researchers at Needham & Company LLC boosted their price target on shares of Aerie Pharmaceuticals (NASDAQ:AERI) from $26.00 to $37.00 in a research report issued on Thursday. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s target price indicates a potential upside of 37.14% from the stock’s previous close.
Aerie Pharmaceuticals (NASDAQ:AERI) traded up 1.93% during mid-day trading on Thursday, hitting $27.50. 286,827 shares of the company’s stock traded hands. Aerie Pharmaceuticals has a one year low of $10.25 and a one year high of $29.71. The stock’s 50-day moving average is $16.91 and its 200-day moving average is $18.28. The company’s market cap is $644.5 million. Aerie Pharmaceuticals also saw a significant decrease in short interest during the month of June. As of June 13th, there was short interest totalling 432,812 shares, a decrease of 25.9% from the May 30th total of 584,343 shares. Approximately 5.0% of the shares of the company are short sold. Based on an average daily volume of 178,623 shares, the days-to-cover ratio is currently 2.4 days.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.28) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.35) by $0.07. On average, analysts predict that Aerie Pharmaceuticals will post $-1.49 earnings per share for the current fiscal year.
Separately, analysts at RBC Capital cut their price target on shares of Aerie Pharmaceuticals from $28.00 to $27.00 in a research note on Tuesday, May 13th. They now have an “outperform” rating on the stock.
Aerie Pharmaceuticals, Inc is a United States-based company. The Company is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.